Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 14.01 USD -0.85% Market Closed
Market Cap: 637m USD
Have any thoughts about
Capricor Therapeutics Inc?
Write Note

Capricor Therapeutics Inc
Investor Relations

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Dr. Frank Isaac Litvack FACC, M.D.
Executive Chairman of the Board
No Bio Available
Dr. Linda Marbán Ph.D.
Co-Founder, President, CEO & Director
No Bio Available
Mr. Anthony J. Bergmann M.B.A.
CFO & Corporate Treasurer
No Bio Available
Ms. Karen G. Krasney
Executive VP, General Counsel & Secretary
No Bio Available
Dr. Kristi A. H. Elliott Ph.D.
Chief Science Officer
No Bio Available
Catherine Lee Kelleher
Consultant
No Bio Available

Contacts

Address
CALIFORNIA
Beverly Hills
8840 Wilshire Blvd Fl 2
Contacts
+13103583200.0
capricor.com